Form 8-K - Current report:
SEC Accession No. 0001213900-22-054504
Filing Date
2022-09-07
Accepted
2022-09-07 16:00:46
Documents
13
Period of Report
2022-09-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea165432-8k_inmunebio.htm   iXBRL 8-K 24276
2 PRESS RELEASE, DATED SEPTEMBER 7, 2022 ea165432ex99-1_inmunebio.htm EX-99.1 10746
  Complete submission text file 0001213900-22-054504.txt   212242

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20220907.xsd EX-101.SCH 3230
4 XBRL LABEL FILE inmb-20220907_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE inmb-20220907_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea165432-8k_inmunebio_htm.xml XML 3709
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 221231174
SIC: 2836 Biological Products, (No Diagnostic Substances)